drugset / Trial / NCT04943016
CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This study seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of a chimeric antigen receptor targeting the B cell surface antigen CD19 following administration of chemotherapy lymphodepletion regimen in children and adults with relapsed/refractory B cell malignancies.
Timeline
- Start
- 2021-07-01
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 Chimeric Antigen Receptor (CAR) T Cells | Cell therapy | 1e+06 cells/kg | — |
| Subject | CD19 Chimeric Antigen Receptor (CAR) T Cells | Cell therapy | 5e+06 cells/kg | — |